<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AJMB</journal-id>
<journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
<issn pub-type="ppub">2008-2835</issn>
<issn pub-type="epub">2008-4625</issn>
<publisher>
<publisher-name>Avicenna Research Institute</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">AJMB-6-81</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An <italic>In silico</italic> Based Comparison of Drug Interactions in Wild and Mutant Human &#x3B2;-tubulin through Docking Studies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chellasamy</surname>
<given-names>Selvaakumar</given-names>
</name>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mohammed</surname>
<given-names>Sudheer M. M.</given-names>
</name>
<xref ref-type="aff" rid="AF0002">2</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Department of Biotechnology and Bioinformatics, Padmashree Dr.D.Y. Patil University, Navi Mumbai, India</aff>
<aff id="AF0002">
<label>2</label>Government Arts College, Coimbatore, India</aff>
<author-notes>
<corresp id="cor1">
<label>&#x002A;</label> <bold>Corresponding author:</bold> Selvaakumar Chellasamy, Department of Biotechnology and Bioinformatics, Padmashree Dr. D.Y. Patil University, Navi Mumbai, India. <bold>Tel:</bold> +91 22 27563600, <bold>Fax:</bold> +91 22 39286176. <bold>E-mail:</bold> <email xlink:href="selvaakumarc@gmail.com">selvaakumarc@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<season>Apr-Jun</season>
<year>2014</year>
</pub-date>
<volume>6</volume>
<issue>2</issue>
<fpage>81</fpage>
<lpage>93</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>06</month>
<year>2013</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>11</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2014 Avicenna Research Institute</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
<p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</p>
</license>
</permissions>
<abstract>
<sec id="st1">
<title>Background</title>
<p>Tubulin protein being the fundamental unit of microtubules is actively involved in cell division thus making them a potential anti-cancer drug target. In spite of many reported drugs against tubulin, few of them have started developing resistance in human &#x3B2;-tubulin due to amino acid substitutions.</p>
</sec>
<sec id="st2">
<title>Methods</title>
<p>In this study we generated three mutants (F270V, A364T and Q292E) using Modeller9v10 which were targeted with compounds from higher and lower plants along with marine isolates using iGEMDOCK2.0 to identify their residual interactions.</p>
</sec>
<sec id="st3">
<title>Results</title>
<p>The mutant F270V does not bring in any increase in the binding affinity in comparison with the taxol-wild type due to their conservative substitutions. However, it increases the volume of the active site. A364T mutant brings a better binding among few of the marine and higher plants isolates due to the substitution of the non-reactive methyl group with the polar residue. But this leads to reduced active site volume. Finally the mutant Q292E from epothilone binding site brings a remarkable change in drug binding in the mutants in comparison with the wild type due to the substitution of uncharged residue with the charged one. But as such there was no change in the volume of the active site observed in them.</p>
</sec>
<sec id="st4">
<title>Conclusion</title>
<p>Lower plants extracts were reported to exhibit better interactions with the taxol and epothilone binding sites. Whereas marine and higher plants isolates shows significant interactions only in the wild type instead of the mutants. In addition to this, the residual substitutions were also found to alter the conformations of the active sites in mutants</p>
</sec>
</abstract>
<kwd-group>
<kwd>Docking</kwd>
<kwd>Epothilones</kwd>
<kwd>Microtubules</kwd>
<kwd>Taxol</kwd>
<kwd>Tubulin</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S0001" sec-type="intro">
<title>Introduction</title>
<p>Tubulin being the fundamental unit of microtubules is critically involved in chromosomal segregation, cell division, motility and intracellular transportation <sup>(<xref ref-type="bibr" rid="CIT0001">1</xref>)</sup>. They are made up of &#x3B1; and &#x3B2; subunits alternatively arranged in a lateral and longitudinal manner. The lateral contacts involve the interactions of H1-S2 loop and helix H3 with the M-loop of the adjacent protofilament. Thus, 13 protofilaments associate laterally and are found to be more electrostatic and less hydrophobic than the longitudinal contacts <sup>(<xref ref-type="bibr" rid="CIT0002">2</xref>&#x2013;<xref ref-type="bibr" rid="CIT0006">6</xref>)</sup>. The alternative arrangement of &#x3B1; and &#x3B2; subunits results in longitudinal interactions which are classified into intra- and interdimer interfaces. The intradimeric interface is observed between &#x3B2; and &#x3B1; subunits whereas the interdimericinterface is found between &#x3B1; and &#x3B2; subunits <sup>(<xref ref-type="bibr" rid="CIT0007">7</xref>&#x2013;<xref ref-type="bibr" rid="CIT0009">9</xref>)</sup>. Further, the longitudinal contact involves the interaction of H8 of &#x3B1; tubulin with H11-H12, T5, T3 and &#x3B3;-phosphate of the adjacent subunit. Similarly, T7 of &#x3B1;-tubulin shows interactions with phosphates T2, T1, H7 and Guanine <sup>(<xref ref-type="bibr" rid="CIT0010">10</xref>)</sup>.</p>
<p>&#x3B2;-tubulin subunit comprises three distinct domains which include the N-terminal domain, intermediate domain and C-terminal domain. The N-terminal domain harbors the nucleotide and has 6 parallel beta strands (S1-S6) along with the same number of alpha helix (H1-H6). The intermediate domain has strands S7-S10 with three helices H8-H10 which accommodates taxol. The C-terminal is made up of two antiparallel helices H11-H12 which interacts with Microtubule Associated Protein (MAP) <sup>(<xref ref-type="bibr" rid="CIT0011">11</xref>)</sup>.</p>
<p>Even though the overall domain architecture remains the same in &#x3B1;- and &#x3B2;-tubulin, still they differentiate themselves both sequentially and structurally. Sequentially they share 40% residual identity, while structurally two positional gaps were observed in &#x3B2;-tubulin at H1-S2 loop (45-46) and S loop (361-368). The larger gap in &#x3B2;-tubulin gets well accommodated by taxol <sup>(<xref ref-type="bibr" rid="CIT0012">12</xref>)</sup>. Both the subunits get well associated with GTP; however, hydrolysis is restricted to &#x3B2;-subunit resulting in GTP formation at the exchangeable site. However, it gets sequestered in non-exchangeable site in &#x3B1; subunit <sup>(<xref ref-type="bibr" rid="CIT0013">13</xref>&#x2013;<xref ref-type="bibr" rid="CIT0023">23</xref>)</sup>.</p>
<p>Tubulin with its active role in cell division has been considered as a potential anticancer drug target <sup>(<xref ref-type="bibr" rid="CIT0024">24</xref>)</sup>. It comprises three distinct drug binding domains which include taxol, vinca-alkaloid and colchicine binding sites. Drugs associated with these sites were religiously involved in arresting the mitotic spindle formation <sup>(<xref ref-type="bibr" rid="CIT0025">25</xref>)</sup>. Further, taxol and colchicine share overlapping residual interactions towards the inner surface of the microtubules <sup>(<xref ref-type="bibr" rid="CIT0026">26</xref>)</sup>. Paclitaxel being the powerful drug for treating several solid tumors including breast, ovarian and non-small cell lung carcinomas <sup>(<xref ref-type="bibr" rid="CIT0027">27</xref>)</sup> prefers to bind with M-loop proximal to S loop resulting in stabilization of lateral interactions of two adjacent protofilaments <sup>(<xref ref-type="bibr" rid="CIT0028">28</xref>)</sup>. The important residues associated with taxol binding include V23, D226, H229, T276, R278, R369 and Gly370. These residues were scattered around H1-S2 loop, H7, M-loop and S-loop <sup>(<xref ref-type="bibr" rid="CIT0020">20</xref>)</sup>. Apart from paclitaxel, epothilones A and B, eleuthe-robin and discodermolide have also been reported to bind to the taxol binding site <sup>(<xref ref-type="bibr" rid="CIT0029">29</xref>)</sup>.</p>
<p>In spite of all these drug interactions, there is a report of drug resistance among these drugs. The main reason being cited is the residual substitutions associated with the drug resistance. Even though literature supports the correlation between the residual substitutions and drug resistance, but still there is a controversy over their role because of the inclusion of pseudogenes during drug resistance analysis <sup>(<xref ref-type="bibr" rid="CIT0030">30</xref>)</sup>. Thus, the debate on the role of residues on drug resistance remains elusive. The reported residual mutations in human &#x3B2;-tubulin include D26E, V60A, S172A, P173A, D197N, E198G, A231T, L240I, F270V, T274P, R282Q, Q292E, R306C, K350N, A364 and Y442C. Several types of resistance have been observed for the drugs like taxol, epothilone, hemiasterlin, 2-methoxyestradiol, vinca alkaloids and indancocine <sup>(<xref ref-type="bibr" rid="CIT0031">31</xref>&#x2013;<xref ref-type="bibr" rid="CIT0037">37</xref>)</sup>.</p>
<p>Previous studies report about drugs resistance and the reduced binding affinity of the available drugs, but still not much has been discussed about the drugs targeted against the mutant proteins. In this paper, we tried to target the available chemical compounds from higher plants, lower plants and seaweed secondary metabolites against wild and the mutants of human &#x3B2;-tubulin to investigate their level of interactions.</p>
</sec>
<sec id="S0002" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>To begin with, human &#x3B2;-tubulin sequence was downloaded from SwissProt database (accession number: Q9BVA1.1) <sup>(<xref ref-type="bibr" rid="CIT0038">38</xref>)</sup>. With no reported crystal structure of human &#x3B2;-tubulin till date, a BLAST-PDB based <sup>(<xref ref-type="bibr" rid="CIT0039">39</xref>)</sup> search was carried out to identify suitable templates. Out of the reported hits, 1JFF was downloaded from Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org">www.rcsb.org</ext-link>) <sup>(<xref ref-type="bibr" rid="CIT0040">40</xref>)</sup> which was further considered as a template (1JFF-B chain) for the modeling of the query sequence. Pairwise alignment of the template and the query sequence were generated using Modeller9v10 <sup>(<xref ref-type="bibr" rid="CIT0041">41</xref>)</sup> (<xref ref-type="fig" rid="F0001">Figure 1</xref>). Using single protocol template from Modeller, 30 structures were generated. Of these generated structures, the model with the least DOPE score (Discrete Optimized Protein Energy) was considered for energy minimization with 100 iterations using steepest descent in SwissPdbViewer <sup>(<xref ref-type="bibr" rid="CIT0042">42</xref>)</sup>. The template and the modelled structures were superimposed with each other (<xref ref-type="fig" rid="F0002">Figure 2A</xref>&#x2013;<xref ref-type="fig" rid="F0002">C</xref>). The DOPE score of the template was -49714.55 and the modelled structure was -55870.25. The optimized structure was further validated using PROCHECK of SAVES server (<ext-link ext-link-type="uri" xlink:href="http://nihserver.mbi.ucla.edu/SAVES/">http://nihserver.mbi.ucla.edu/SAVES/</ext-link>) <sup>(<xref ref-type="bibr" rid="CIT0043">43</xref>)</sup>. Similar methods were followed for the generation of mutants F270V, A364T and Q292E, respectively.</p>
<fig id="F0001">
<label>Figure 1</label>
<caption>
<p>Pairwise sequence alignment of template (1JFF-B chain) with the query sequence of human &#x3B2;-tubulin</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-6-81-g001.tif" alt-version="no"/>
</fig>
<fig id="F0002">
<label>Figure 2</label>
<caption>
<p>3D structure of the template; A) the modelled structure of human &#x3B2;-tubulin; B) and its structural superimposition C)</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-6-81-g002.tif" alt-version="no"/>
</fig>
<p>Conversely, chemical compounds needed for docking against wild and the mutants of human &#x3B2;-tubulin were obtained from marine flora. The chemical compounds were obtained from seaweed secondary metabolite database (<ext-link ext-link-type="uri" xlink:href="http://www.swmd.co.in">www.swmd.co.in</ext-link>) <sup>(<xref ref-type="bibr" rid="CIT0044">44</xref>)</sup>. All these available compounds were isolated form red algae Laurencia obtuse (RL) and Galaxaura marginata (RG type). Some of these compounds were reported to be cytotoxic against cancer cell lines <sup>(<xref ref-type="bibr" rid="CIT0045">45</xref>&#x2013;<xref ref-type="bibr" rid="CIT0049">49</xref>)</sup>. During our previous study, out of the 517 compounds, we could identify four lead compounds named RG012 (6&#x3B2;, 24&#603;-Dihydroxycholesta-4, 25-dien-3-one), RL381 (diterpenes containing bromine), RL366 (15-epi-prostaglandin A2 diester), and RL376 (diterpenes containing bromine) which exhibit better binding to wild type human &#x3B2;-tubulin protein <sup>(<xref ref-type="bibr" rid="CIT0050">50</xref>)</sup>. All these selected compounds were taken into consideration for docking against the wild and mutant human &#x3B2;-tubulin proteins in the current study.</p>
<p>Next, through literature survey, we identified chemical compounds both from higher and lower plants. To begin with, the compounds from higher plants include Berbamine, Butulinic acid, Camptothecin, Cucurbitacin, Ellipticine, Flavopiridol, Homoharringtonine, Silvestrol, Berberine, Daphnoretin and Podophyllotoxin. Regarding their sources, Berbamine is extracted from <italic>Berberis vulgaris</italic> with a reported apoptosis in human myeloma cells <sup>(<xref ref-type="bibr" rid="CIT0051">51</xref>, <xref ref-type="bibr" rid="CIT0052">52</xref>)</sup>. Betulinic acid is a pentacyclic triterpenoid with reported antiretroviral, antimalarial and anti-inflammatory activity and anticancer properties extracted from the bark of <italic>Betula pubescens</italic> <sup>(<xref ref-type="bibr" rid="CIT0053">53</xref>, <xref ref-type="bibr" rid="CIT0054">54</xref>)</sup>.</p>
<p>Camptothecin isolated from the bark and stem of Camptotheca acuminate is a cytotoxic quinoline alkaloid which inhibits the DNA enzyme topoisomerase I <sup>(<xref ref-type="bibr" rid="CIT0055">55</xref>)</sup>. Cucurbitacins are from the family of Cucurbitaceae with anti-cancer and anti-inflammatory activities <sup>(<xref ref-type="bibr" rid="CIT0056">56</xref>)</sup>. Podophyllotoxin is a non-alkaloid toxin lignan extracted from the roots and rhizomes of <italic>Podophyllum</italic> species which is again an antitumor agent <sup>(<xref ref-type="bibr" rid="CIT0057">57</xref>&#x2013;<xref ref-type="bibr" rid="CIT0059">59</xref>)</sup>. Silvestrol is isolated from <italic>Aglaia foveolata</italic> and results in apoptosis in the cell lines of hormone-dependent human prostate cancer <sup>(<xref ref-type="bibr" rid="CIT0060">60</xref>)</sup>. Homoharringtonine is extracted from <italic>Cephalotaxus harringtonia</italic> which is identified to be a cytotoxic alkaloid and is generally reported to block the progression of cells from G1 phase in to S phase and G2 phase into M phase <sup>(<xref ref-type="bibr" rid="CIT0061">61</xref>)</sup>. Flavopiridol is an indigenous plant from India, which can arrest cell cycle progression at the G1/S and G2/M boundaries <sup>(<xref ref-type="bibr" rid="CIT0062">62</xref>)</sup>. Daphnoretin obtained from <italic>Wikstroemia indica</italic> exhibits strong antiviral and anti-tumor activities with a report of cell cycle arrest in the G2/M phase <sup>(<xref ref-type="bibr" rid="CIT0063">63</xref>)</sup>. Ellipticine is isolated from Apocyanaceae plants with established antitumor and anti-HIV activities with their limited toxic side effects and their lack of hematological toxicity <sup>(<xref ref-type="bibr" rid="CIT0064">64</xref>)</sup>.</p>
<p>Regarding lower plants, Aclarubicin is produced by <italic>Streptomyces galilaeus</italic> actively used in the treatment of cancer <sup>(<xref ref-type="bibr" rid="CIT0065">65</xref>)</sup>. Daunorubicin and its derivative, doxorubicinare antitumor anthracycline antibiotics are produced by <italic>Streptomyces peucetius</italic> <sup>(<xref ref-type="bibr" rid="CIT0066">66</xref>)</sup>. Blasticidin is a potent antifungal and cytotoxic peptidyl nucleoside antibiotic from <italic>Streptomyces griseo-chromogenes</italic> which plays a significant role in controlling prokaryotic and eukaryotic cell growth <sup>(<xref ref-type="bibr" rid="CIT0067">67</xref>)</sup>. Chartreusin is a potent antitumor agent with a mixed polyketide-carbohydrate structure produced by <italic>Streptomyces chartreu-sis</italic> <sup>(<xref ref-type="bibr" rid="CIT0068">68</xref>)</sup>. Neothramycin has been isolated from Streptomyces MC916-C4 which is a potent antitumor antibiotic of the pyrrolo (l, 4) benzodiazepine group <sup>(<xref ref-type="bibr" rid="CIT0069">69</xref>, <xref ref-type="bibr" rid="CIT0070">70</xref>)</sup>. Pirarubicin is an anthracycline drug which has a diversified antitumor activity <sup>(<xref ref-type="bibr" rid="CIT0071">71</xref>, <xref ref-type="bibr" rid="CIT0072">72</xref>)</sup>. All these chemical compounds were downloaded from Pubchem database. The chemical structures were obtained from chemical book (<ext-link ext-link-type="uri" xlink:href="http://www.Chemical-book.com">www.Chemical-book.com</ext-link>) (<xref ref-type="table" rid="T0001">Table 1</xref>). The summary of the chemical compounds of lower and higher floras along with marine derivates are tabulated in <xref ref-type="table" rid="T0002">Table 2</xref>.
</p>
<table-wrap id="T0001">
<label>Table 1</label>
<caption>
<p>Chemical structures of higher and lower plants along with marine compounds</p>
</caption>
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="left">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-6-81-ug001.tif" alt-version="no"/></td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T0002">
<label>Table 2</label>
<caption>
<p>Summary of chemical compounds of lower and higher floras along with marine derivatives</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Chemical compounds</th>
<th align="center">Molecular weight (<italic>g/mol</italic>)</th>
<th align="center">xlogP3</th>
<th align="center">H-bond donor</th>
<th align="center">H-bond acceptor</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">
<bold>Aclarubicin</bold>
</td>
<td align="center">811.86</td>
<td align="center">3.8</td>
<td align="center">4</td>
<td align="center">16</td>
</tr>
<tr>
<td align="left">
<bold>Blasticidin</bold>
</td>
<td align="center">422.43</td>
<td align="center">-5.2</td>
<td align="center">6</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">
<bold>Chartreusin</bold>
</td>
<td align="center">640.58</td>
<td align="center">2.1</td>
<td align="center">5</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">
<bold>Daunorubicin</bold>
</td>
<td align="center">527.51</td>
<td align="center">1.8</td>
<td align="center">5</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">
<bold>Neothramycin</bold>
</td>
<td align="center">262.26</td>
<td align="center">0.2</td>
<td align="center">2</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">
<bold>Pirarubicin</bold>
</td>
<td align="center">627.63</td>
<td align="center">2.7</td>
<td align="center">5</td>
<td align="center">13</td>
</tr>
<tr>
<td align="left">
<bold>RL376</bold>
</td>
<td align="center">418.52</td>
<td align="center">3.1</td>
<td align="center">1</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">
<bold>RL366</bold>
</td>
<td align="center">695.81</td>
<td align="center">8.6</td>
<td align="center">2</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">
<bold>RL381</bold>
</td>
<td align="center">478.58</td>
<td align="center">2.6</td>
<td align="center">2</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">
<bold>RG012</bold>
</td>
<td align="center">414.62</td>
<td align="center">4.6</td>
<td align="center">2</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">
<bold>Berbamine</bold>
</td>
<td align="center">608.72</td>
<td align="center">6.1</td>
<td align="center">1</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">
<bold>Butulinic acid</bold>
</td>
<td align="center">456.70</td>
<td align="center">8.94</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">
<bold>Camptothecin</bold>
</td>
<td align="center">348.35</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">
<bold>Cucurbitacin</bold>
</td>
<td align="center">514.65</td>
<td align="center">2.7</td>
<td align="center">4</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">
<bold>Ellipticine</bold>
</td>
<td align="center">246.30</td>
<td align="center">4.8</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">
<bold>Flavopiridol</bold>
</td>
<td align="center">401.84</td>
<td align="center">3.3</td>
<td align="center">3</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">
<bold>Homoharringtonine</bold>
</td>
<td align="center">545.62</td>
<td align="center">0.8</td>
<td align="center">2</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">
<bold>Silvestrol</bold>
</td>
<td align="center">654.65</td>
<td align="center">1.6</td>
<td align="center">4</td>
<td align="center">13</td>
</tr>
<tr>
<td align="left">
<bold>Berberine</bold>
</td>
<td align="center">336.36</td>
<td align="center">3.6</td>
<td align="center">0</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">
<bold>Daphnoretin</bold>
</td>
<td align="center">352.29</td>
<td align="center">3.3</td>
<td align="center">1</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">
<bold>Taxol</bold>
</td>
<td align="center">853.90</td>
<td align="center">2.5</td>
<td align="center">4</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">
<bold>Epothilone</bold>
</td>
<td align="center">493.65</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">
<bold>Podophyllotoxin</bold>
</td>
<td align="center">414.40</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">8</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>All these selected compounds were charged using gasteiger charges available in CHIMERA software <sup>(<xref ref-type="bibr" rid="CIT0073">73</xref>)</sup>. Energy was minimized using PRODRG and hydrogen atoms were added to them. Then these compounds were considered for docking using iGEMDOCK software <sup>(<xref ref-type="bibr" rid="CIT0074">74</xref>)</sup>. The active sites of taxol (V23, D226, H229, T276, R278, R369 and Gly370) and epothilone (H227, A231, T274, R276, R282 and Q292) <sup>(<xref ref-type="bibr" rid="CIT0075">75</xref>)</sup> were selected for docking (<xref ref-type="fig" rid="F0003">Figure 3</xref>). Next, only the residual mutants with deleterious effects were considered for homology modelling. This was identified using amino acid substitution (AAS) tools like Polyphen2 (poly morphism phenotyping) <sup>(<xref ref-type="bibr" rid="CIT0076">76</xref>, <xref ref-type="bibr" rid="CIT0077">77</xref>)</sup>, PANTHER (protein analysis through evolutionary relationship) <sup>(<xref ref-type="bibr" rid="CIT0078">78</xref>)</sup> and I-Mutant 2.0 <sup>(<xref ref-type="bibr" rid="CIT0079">79</xref>)</sup>. The list of residual substitutions which bring in deleterious effects are tabulated (<xref ref-type="table" rid="T0003">Table 3</xref>) (for detailed report refer) <sup>(<xref ref-type="bibr" rid="CIT0080">80</xref>)</sup>. Out of ten deleterious sites identified, only three were selected as these substitutions were found to be proximal to the drug binding sites. Unfortunately, the rest of the positions were located at distal sites of both taxol and epothilone binding sites. Docking of the lower and higher plants along with marine isolates were carried out using iGEM DOCK for taxol-wild, taxol-mutants (F270V, A364T), epothilone-wild and epothilone-mutant (Q292E). The docking study followed the accurate docking protocol which was very slow with population size of 800 and the number of solution equal to 10. The generation number was maintained at 80. Similar protocol was followed for taxol and epothilone binding pockets. Finally, we measured the size of the normal grooves for wild and the mutants of taxol and epothilone binding sites using SwissPdbViewer.
</p>
<fig id="F0003">
<label>Figure 3</label>
<caption>
<p>Drug binding sites in human &#x3B2;-tubulin for epothilone (Red) and taxol (Blue)</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-6-81-g003.tif" alt-version="no"/>
</fig>
<table-wrap id="T0003">
<label>Table 3</label>
<caption>
<p>Predicting the effect of residual substitutions through amino acid substitutions tools Polyphen2, PANTHER and I-Mutant2.0</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="3" valign="middle">Residual position</th>
<th align="center" colspan="2">Polyphen2</th>
<th align="center">PANTHER</th>
<th align="center">I-Mutant 2.0</th>
</tr>
<tr>
<th colspan="4">
<hr/>
</th>
</tr>
<tr>
<th align="center" colspan="2">Prediction score</th>
<th align="center">Pdeleterious</th>
<th align="center">(in <italic>kcal/mol</italic>)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">
<bold>V60A</bold>
</td>
<td align="center">0.88</td>
<td align="center">Possibly damaging</td>
<td align="center">0.81</td>
<td align="center">-2.2</td>
</tr>
<tr>
<td align="left">
<bold>P173A</bold>
</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="center">0.67</td>
<td align="center">-1.9</td>
</tr>
<tr>
<td align="left">
<bold>D197N</bold>
</td>
<td align="center">0.99</td>
<td align="center">Probably damaging</td>
<td align="center">0.84</td>
<td align="center">-0.37</td>
</tr>
<tr>
<td align="left">
<bold>L240I</bold>
</td>
<td align="center">0.95</td>
<td align="center">Probably damaging</td>
<td align="center">0.68</td>
<td align="center">-1.12</td>
</tr>
<tr>
<td align="left">
<bold>F270V</bold>
</td>
<td align="center">0.9</td>
<td align="center">Possibly damaging</td>
<td align="center">0.5</td>
<td align="center">-1.66</td>
</tr>
<tr>
<td align="left">
<bold>Q292E</bold>
</td>
<td align="center">0.99</td>
<td align="center">Probably damaging</td>
<td align="center">0.6</td>
<td align="center">0.28</td>
</tr>
<tr>
<td align="left">
<bold>R306C</bold>
</td>
<td align="center">1</td>
<td align="center">Probably damaging</td>
<td align="center">0.9</td>
<td align="center">0.1</td>
</tr>
<tr>
<td align="left">
<bold>K350N</bold>
</td>
<td align="center">0.99</td>
<td align="center">Probably damaging</td>
<td align="center">0.79</td>
<td align="center">-0.75</td>
</tr>
<tr>
<td align="left">
<bold>A364T</bold>
</td>
<td align="center">0.88</td>
<td align="center">Probably damaging</td>
<td align="center">0.76</td>
<td align="center">-1.3</td>
</tr>
<tr>
<td align="left">
<bold>Y422C</bold>
</td>
<td align="center">1</td>
<td align="center">Probably damaging</td>
<td align="center">0.92</td>
<td align="center">1.54</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="S0003" sec-type="results">
<title>Results</title>
<p>In the present study, the chemical compounds obtained from different resources like lower plants, higher plants and marine isolates were docked against the wild and the mutant human &#x3B2;-tubulin proteins. This study was mainly instigated to identify the level of interactions exhibited by both the wild and the mutants for taxol resistance (F270V, A364) and epothilone resistance (Q292). For this study, we considered the results of our previously reported lead molecules from seaweed secondary metabolites. Simultaneously, the chemical compounds from lower and higher plants were also taken into consideration.</p>
<p>First of all, the wild tubulin when docked with these compounds exhibited better binding to Aclarubicin. Next, the compounds from higher plants like Berbamine, Butulinic acid, Cucurbitacin, taxol and Podophyllotoxin exhibited better interactions in the wild type in the taxol binding site similar to the marine compounds. Next, the mutants were considered for docking with all the available compounds. Here, Campothecin, Flavopiridol and Berberine exhibited better interactions in mutant1 (F27 0V). This site is proximal to M-loop and is also the taxol binding site. With respect to mutant2 (A364T), the chemical compounds like Camptothecin, Ellipticine, Flavopiridol, Berberine, Daphnoretin showed better chemical interactions. In epothilone binding site, lower plant compounds like Aclarubicin and Blasticidin showed better interaction in the wild type. The compounds like Neothramycin, Daunorubicin and Aclarubicin showed slightly better interaction with the mutation of glutamate with Glu at residual position 292. Thus, our overall study confirms that marine compounds exhibit better interaction in this mutant protein except RL376. Among higher plant products, Camptothecin, Ellipticine, Epothilone, Podophyllotoxin exhibit better interaction in the wild type of epothilone binding site. But compounds like Berbamine, Flavopiridol, Berberine and Daphnoretin conveyed better interactions again in the mutant (<xref ref-type="table" rid="T0004">Table 4</xref>). General survey confirms a similar type of interactions exhibited both by wild and the mutant proteins. Thus, a closer inspection of the pocket was much needed for both sets of proteins. Therefore, we measured the groove size for wild, F270V and A364T of the taxol binding site. The volume was 550, 607 and 220 &#x00C5;<sup>(<xref ref-type="bibr" rid="CIT0003">3</xref>)</sup> respectively. However, for epothilone binding pockets, the wild and the mutant (Q292E) maintained same volume of 8 &#x00C5;<sup>(<xref ref-type="bibr" rid="CIT0003">3</xref>)</sup>. There was an increase in pocket volume observed for mutant1 in comparison with the wild type due to non-conservative residual substitution. Similarly, the volume of mutant2 decreases in comparison with the wild type in spite of conservative substitution. However, in epothilone binding site, the conservative substitution does not bring in any change in the volume both in wild and the mutant and the grooves were found to be discontinuous with the maximum volume size of 8 &#x00C5;<sup>(<xref ref-type="bibr" rid="CIT0003">3</xref>)</sup> (<xref ref-type="fig" rid="F0004">Figure 4</xref>).
</p>
<fig id="F0004">
<label>Figure 4</label>
<caption>
<p>The groove of the active site pockets in wild and the mutant human &#x3B2;-tubulin; A) wild-taxol binding site; B) mutant1-taxol binding site; C) mutant2-taxol binding site; D) wild-epothilone binding site; E) mutant-epothilone binding site</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-6-81-g004.tif" alt-version="no"/>
</fig>
<table-wrap id="T0004">
<label>Table 4</label>
<caption>
<p>Docking of chemical compounds from lower, higher and marine resources against taxol and epothilone binding sites in wild and mutant proteins</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="3" valign="middle">Origin</th>
<th align="center" rowspan="3" valign="middle">Compounds</th>
<th align="center" colspan="3">Taxol binding site (binding energy in <italic>kcal/mol</italic>)</th>
<th align="center" colspan="2">Epothilone binding site (binding energy in <italic>kcal/mol</italic>)</th>
</tr>
<tr>
<th colspan="5">
<hr/>
</th>
</tr>
<tr>
<th align="center">Wild</th>
<th align="center">Mutant1 (F270V)</th>
<th align="center">Mutant2 (A364T)</th>
<th align="center">Wild</th>
<th align="center">Mutant (Q292E)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="6" valign="middle">
<bold>Lower plants</bold>
</td>
<td align="left">Aclarubicin</td>
<td align="center">-125.84</td>
<td align="center">-121.20</td>
<td align="center">-96.84</td>
<td align="center">-69.66</td>
<td align="center">-69.68</td>
</tr>
<tr>
<td align="left">Blasticidin</td>
<td align="center">65.17</td>
<td align="center">13.35</td>
<td align="center">88.07</td>
<td align="center">-33.98</td>
<td align="center">72.76</td>
</tr>
<tr>
<td align="left">chartreusin</td>
<td align="center">319.11</td>
<td align="center">38.04</td>
<td align="center">388.28</td>
<td align="center">221.045</td>
<td align="center">54.33</td>
</tr>
<tr>
<td align="left">Daunorubicin</td>
<td align="center">207.93</td>
<td align="center">-4.9</td>
<td align="center">46.49</td>
<td align="center">0.45</td>
<td align="center">-11.00</td>
</tr>
<tr>
<td align="left">Neothramycin</td>
<td align="center">-66.27</td>
<td align="center">-66.98</td>
<td align="center">69.74</td>
<td align="center">-28.26</td>
<td align="center">-31.36</td>
</tr>
<tr>
<td align="left">Pirarubicin</td>
<td align="center">90.65</td>
<td align="center">95.46</td>
<td align="center">50.78</td>
<td align="center">332.44</td>
<td align="center">66.66</td>
</tr>
<tr>
<td align="left" rowspan="4" valign="middle">
<bold>Marine compounds</bold>
</td>
<td align="left">RL376</td>
<td align="center">-86.97</td>
<td align="center">-83.51</td>
<td align="center">-81.81</td>
<td align="center">-45.38</td>
<td align="center">-33.72</td>
</tr>
<tr>
<td align="left">RL366</td>
<td align="center">-82.61</td>
<td align="center">-79.19</td>
<td align="center">-81.44</td>
<td align="center">-30.86</td>
<td align="center">-37.99</td>
</tr>
<tr>
<td align="left">RL381</td>
<td align="center">-78.16</td>
<td align="center">-75.38</td>
<td align="center">-79.92</td>
<td align="center">-28.33</td>
<td align="center">-30.66</td>
</tr>
<tr>
<td align="left">RG012</td>
<td align="center">-77.55</td>
<td align="center">-76.07</td>
<td align="center">-65.17</td>
<td align="center">-38.40</td>
<td align="center">-38.49</td>
</tr>
<tr>
<td align="left" rowspan="13" valign="middle">
<bold>Higher plants</bold>
</td>
<td align="left">Berbamine</td>
<td align="center">-19.55</td>
<td align="center">235.23</td>
<td align="center">129.56</td>
<td align="center">26.44</td>
<td align="center">-33.49</td>
</tr>
<tr>
<td align="left">Butulinic acid</td>
<td align="center">-79.00</td>
<td align="center">-17.77</td>
<td align="center">-15.62</td>
<td align="center">-20.91</td>
<td align="center">2.02</td>
</tr>
<tr>
<td align="left">Camptothecin</td>
<td align="center">-82.97</td>
<td align="center">-79.27</td>
<td align="center">-86.75</td>
<td align="center">-44.01</td>
<td align="center">-43.85</td>
</tr>
<tr>
<td align="left">Cucurbitacin</td>
<td align="center">-86.92</td>
<td align="center">-84.52</td>
<td align="center">-78.20</td>
<td align="center">-24.33</td>
<td align="center">-24.36</td>
</tr>
<tr>
<td align="left">Ellipticine</td>
<td align="center">-66.21</td>
<td align="center">-64.62</td>
<td align="center">-75.40</td>
<td align="center">-39.95</td>
<td align="center">-15.65</td>
</tr>
<tr>
<td align="left">Flavopiridol</td>
<td align="center">-67.46</td>
<td align="center">-69.65</td>
<td align="center">-74.93</td>
<td align="center">-4.32</td>
<td align="center">-39.29</td>
</tr>
<tr>
<td align="left">Homoharringtonine</td>
<td align="center">107.36</td>
<td align="center">145.86</td>
<td align="center">13.95</td>
<td align="center">181.80</td>
<td align="center">7.39</td>
</tr>
<tr>
<td align="left">Silvestrol</td>
<td align="center">133.96</td>
<td align="center">153.26</td>
<td align="center">57.28</td>
<td align="center">43.01</td>
<td align="center">25.84</td>
</tr>
<tr>
<td align="left">Berberine</td>
<td align="center">-75.72</td>
<td align="center">-81.20</td>
<td align="center">-82.74</td>
<td align="center">-29.36</td>
<td align="center">-36.08</td>
</tr>
<tr>
<td align="left">Daphnoretin</td>
<td align="center">-80.37</td>
<td align="center">-79.21</td>
<td align="center">-82.75</td>
<td align="center">-34.01</td>
<td align="center">-37.03</td>
</tr>
<tr>
<td align="left">Taxol</td>
<td align="center">-82.60</td>
<td align="center">-79.20</td>
<td align="center">-81.48</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">Epothilone</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">-37.10</td>
<td align="center">-21.84</td>
</tr>
<tr>
<td align="left">Podophyllotoxin</td>
<td align="center">-83.00</td>
<td align="center">-80.23</td>
<td align="center">-75.71</td>
<td align="center">-40.19</td>
<td align="center">-38.18</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="S0004" sec-type="discussion">
<title>Discussion</title>
<p>During the docking of the wild and the mutants against the available compounds, only three mutants were generated which were proximal to the drug binding site, and were also reported to be lethal. Thus, the generated mutants were christened as mutant1 (F270V) mutant2 (A364T) for the taxol binding site. Similarly, mutant (Q292E) was selected for epothilone binding site. Docked structures were separately investigated for their interactions using CHIMERA software. We observed that Neothramycin exhibits interactions with the taxol binding site through P272 and R276 (<xref ref-type="fig" rid="F0005">Figure 5A</xref>). Similar interactions were exhibited by mutant1 (<xref ref-type="fig" rid="F0006">Figure 6A</xref>). Also mutant2 exhibited interaction with L361 (<xref ref-type="fig" rid="F0006">Figure 6B</xref>). Likewise, RL381 displayed interactions in the wild type of taxol binding site with H227, R282, and R359 (<xref ref-type="fig" rid="F0005">Figure 5B</xref>). Camptothecin shows interaction with T274 (<xref ref-type="fig" rid="F0005">Figure 5C</xref>) while taxol based mutants, irrespective of their higher binding energy, do not display any interactions. Ellipticine also confirms no significant binding in mutant2. Flavopiridol does not show any significant interactions in the wild taxol binding site. But mutant1 shows interaction with H227 (<xref ref-type="fig" rid="F0006">Figure 6C</xref>). Also mutant2 shows interactions with T274 and A275 (<xref ref-type="fig" rid="F0006">Figure 6D</xref>). Berberine also shows no significant interaction in the wild type and mutant2 of taxol binding site but mutant1 confirms their interaction with R276 (<xref ref-type="fig" rid="F0006">Figure 6E</xref>). Again with Daphnoretin, both wild and mutant2 show no interactions, but mutant1 interacts with R276 (<xref ref-type="fig" rid="F0006">Figure 6F</xref>). Next, regarding the epothilone binding site, Neothramycin binds with mutant at T274 (<xref ref-type="fig" rid="F0007">Figure 7A</xref>). RL366 interacts in the mutant with R276 (<xref ref-type="fig" rid="F0007">Figure 7B</xref>). However, the rest of the compounds like RL381, Flavopiridol, Berberine and Daphnoretin exhibited no significant interactions. Since no remarkable change in the pattern of interactions both in wild and the mutant was observed, we considered the groove analysis for the taxol and the epothilone binding site. This study confirms an increase in the channel size for mutant1 and a decrease in the channel size for mutant2 in comparison with wild type. Moreover, epothilone binding site remains undisturbed with the residual substitution. We hypothesized that the drug resistance especially for taxol binding drugs could be related to the conformational changes in the active site pocket due to residual mutations.</p>
<fig id="F0005">
<label>Figure 5</label>
<caption>
<p>The docking of chemical compounds in the taxol binding sites of wild human &#x3B2;-tubulin; A) Neothramycin-taxol-wild; B) RL381-taxol-wild; C) Camptothecin-taxol-wild</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-6-81-g005.tif" alt-version="no"/>
</fig>
<fig id="F0006">
<label>Figure 6</label>
<caption>
<p>The docking of chemical compounds in the taxol binding sites of mutant human &#x3B2;-tubulin. A) Neothramycin-taxol-mutant1; B) Flavopiridol-taxol-mutant1; C) Berberine-taxol-mutant1; D) Daphnoretin-taxol-mutant1; E) Neothramycin-taxol-mutant2; F) Flavopiridol-taxol-mutant2</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-6-81-g006.tif" alt-version="no"/>
</fig>
<fig id="F0007">
<label>Figure 7</label>
<caption>
<p>The docking of chemical compounds in the epothilone binding sites of mutant (Q292E) human &#x3B2;-tubulin. A) Neothramycin-epothilone-mutant; B) RL366-epothilone-mutant</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-6-81-g007.tif" alt-version="no"/>
</fig>
</sec>
<sec id="S0005" sec-type="conclusion">
<title>Conclusion</title>
<p>The residual interaction analysis in wild and the mutants of taxol and epothilone binding sites reveals a better drug binding with the lower plants in the wild types of taxol and epothilone. However, the marine compound and the higher plants in spite of their increase in binding score could not establish a better contact with the residues of both the binding sites. Further, the chemical compounds showed interactions with the charged residues like arginine and histidine for better drug binding.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgement</title>
<p>The authors acknowledge the cooperation of Padmashree Dr. D.Y. Patil University, CBD Belapur for providing the facilities to carry out this work.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="CIT0001">
<label>1</label>
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Hyams</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lloyd</surname>
<given-names>CW</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Harford</surname>
<given-names>JB</given-names>
</name>
</person-group>
<article-title>Microtubules</article-title>
<source>Modern Cell Biology</source>
<year>1994</year>
<publisher-loc>New York</publisher-loc>
<publisher-name>Wiley-Liss</publisher-name>
<fpage>439</fpage>
</nlm-citation>
</ref>
<ref id="CIT0002">
<label>2</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ludvena</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>The multiple forms of tubulin; different gene products and covalent modifications</article-title>
<source>Int Rev Cytol</source>
<year>1998</year>
<volume>178</volume>
<fpage>207</fpage>
<lpage>275</lpage>
</nlm-citation>
</ref>
<ref id="CIT0003">
<label>3</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nogales</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Structural intermediates in microtubule assembly and dissembly: How and Why?</article-title>
<source>Curr Opin Cell Biol</source>
<year>2006</year>
<volume>18</volume>
<issue>2</issue>
<fpage>179</fpage>
<lpage>184</lpage>
</nlm-citation>
</ref>
<ref id="CIT0004">
<label>4</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schek</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Odde</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Microtubule assembly dynamics at the nano-scale</article-title>
<source>Curr Biol</source>
<year>2007</year>
<volume>17</volume>
<issue>17</issue>
<fpage>1445</fpage>
<lpage>1455</lpage>
</nlm-citation>
</ref>
<ref id="CIT0005">
<label>5</label>
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Dustin</surname>
<given-names>P</given-names>
</name>
</person-group>
<source>Microtubules</source>
<year>1984</year>
<publisher-loc>Heidelberg</publisher-loc>
<publisher-name>Springer-Verlag</publisher-name>
</nlm-citation>
</ref>
<ref id="CIT0006">
<label>6</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Mandelkow</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The anatomy of flagellar microtubules: polarity, seam functions and lattice</article-title>
<source>J Cell Biol</source>
<year>1995</year>
<volume>128</volume>
<issue>1-2</issue>
<fpage>81</fpage>
<lpage>94</lpage>
</nlm-citation>
</ref>
<ref id="CIT0007">
<label>7</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caplow</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruhlen</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Shanks</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The free energy for hydrolysis of a microtubule-bound nucleotide triphosphate is nearly zero: all of the free energy for hydrolysis is stored in the microtubule lattice</article-title>
<source>J Cell Biol</source>
<year>1994</year>
<volume>127</volume>
<issue>3</issue>
<fpage>779</fpage>
<lpage>788</lpage>
</nlm-citation>
</ref>
<ref id="CIT0008">
<label>8</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mickey</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Rigidity of microtubules is increased by stabilizing agents</article-title>
<source>J Cell Biol</source>
<year>1995</year>
<volume>130</volume>
<issue>4</issue>
<fpage>909</fpage>
<lpage>917</lpage>
</nlm-citation>
</ref>
<ref id="CIT0009">
<label>9</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyman</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Karsenti</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Morphogenetic properties of microtubules and mitotic spindle assembly</article-title>
<source>Cell</source>
<year>1996</year>
<volume>84</volume>
<issue>3</issue>
<fpage>401</fpage>
<lpage>410</lpage>
</nlm-citation>
</ref>
<ref id="CIT0010">
<label>10</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nogales</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Whittaker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Milligan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Downing</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>High resolution model of the microtubule</article-title>
<source>Cell</source>
<year>1999</year>
<volume>96</volume>
<issue>1</issue>
<fpage>79</fpage>
<lpage>88</lpage>
</nlm-citation>
</ref>
<ref id="CIT0011">
<label>11</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>L&#x00F6;we</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Downing</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Nogales</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Refined structure of alpha beta-tubulin at 3.5 &#x00C5; resolution</article-title>
<source>J Mol Biol</source>
<year>2001</year>
<volume>313</volume>
<issue>5</issue>
<fpage>1045</fpage>
<lpage>1057</lpage>
</nlm-citation>
</ref>
<ref id="CIT0012">
<label>12</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nogales</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Downing</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Amos</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Tubulin and Ftsz form a distinct family of GTPases</article-title>
<source>Nat Struct Biol</source>
<year>1998</year>
<volume>5</volume>
<issue>6</issue>
<fpage>451</fpage>
<lpage>458</lpage>
</nlm-citation>
</ref>
<ref id="CIT0013">
<label>13</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nogales</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Downing</surname>
<given-names>KH</given-names>
</name>
</person-group>
<article-title>Structure of the &#x03B1;&#x03B2; tubulin dimer by electron crystallography</article-title>
<source>Nature</source>
<year>1998</year>
<volume>391</volume>
<issue>6663</issue>
<fpage>199</fpage>
<lpage>203</lpage>
</nlm-citation>
</ref>
<ref id="CIT0014">
<label>14</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirschner</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Weingarten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gerhart</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Microtubules from mammalian brain: some properties of their depolymerization products and proposed mechanism of assembly and disassembly</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1974</year>
<volume>71</volume>
<issue>4</issue>
<fpage>1159</fpage>
<lpage>1163</lpage>
</nlm-citation>
</ref>
<ref id="CIT0015">
<label>15</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howard</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Timasheff</surname>
<given-names>SN</given-names>
</name>
</person-group>
<article-title>GDP state of tubulin: stabilization of double rings</article-title>
<source>Biochemistry</source>
<year>1986</year>
<volume>25</volume>
<issue>25</issue>
<fpage>8292</fpage>
<lpage>8300</lpage>
</nlm-citation>
</ref>
<ref id="CIT0016">
<label>16</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Carlier</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Pantaloni</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Timasheff</surname>
<given-names>SN</given-names>
</name>
</person-group>
<article-title>Cold depolymerization of microtubules to double rings: geometric stabilization of assemblies</article-title>
<source>Biochemistry</source>
<year>1989</year>
<volume>28</volume>
<issue>23</issue>
<fpage>9143</fpage>
<lpage>9152</lpage>
</nlm-citation>
</ref>
<ref id="CIT0017">
<label>17</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandelkow</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Mandelkow</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Milligan</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Microtubule dynamics and microtubule caps: a time resolved cryo-electron microscopy study</article-title>
<source>J Cell Biol</source>
<year>1991</year>
<volume>114</volume>
<issue>5</issue>
<fpage>977</fpage>
<lpage>991</lpage>
</nlm-citation>
</ref>
<ref id="CIT0018">
<label>18</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D&#x00ED;az</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Pantos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bordas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Andreu</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Solution structure of GDP-tubulin double rings to 3 nm resolution and comparison with microtubules</article-title>
<source>J Mol Biol</source>
<year>1994</year>
<volume>238</volume>
<issue>2</issue>
<fpage>214</fpage>
<lpage>225</lpage>
</nlm-citation>
</ref>
<ref id="CIT0019">
<label>19</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nogales</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Niederstrasser</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Tubulin rings: which way do they curve?</article-title>
<source>Curr Opin Struct Biol</source>
<year>2003</year>
<volume>13</volume>
<issue>2</issue>
<fpage>256</fpage>
<lpage>261</lpage>
</nlm-citation>
</ref>
<ref id="CIT0020">
<label>20</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amos</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>How taxol stabilizes microtubule structure chemistry and biology?</article-title>
<source>Chem Biol</source>
<year>1999</year>
<volume>6</volume>
<issue>3</issue>
<fpage>R65</fpage>
<lpage>R69</lpage>
</nlm-citation>
</ref>
<ref id="CIT0021">
<label>21</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mitchison</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Microtubule polymerization dynamics</article-title>
<source>Ann Rev Cell Dev Biol</source>
<year>1997</year>
<volume>13</volume>
<fpage>83</fpage>
<lpage>117</lpage>
</nlm-citation>
</ref>
<ref id="CIT0022">
<label>22</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ravelli</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Gigant</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Curmi</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Jourdain</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lachkar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sobel</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Insight into tubulin regulation from a complex with colchicines and a stathmin-like domain</article-title>
<source>Nature</source>
<year>2004</year>
<volume>428</volume>
<issue>6979</issue>
<fpage>198</fpage>
<lpage>202</lpage>
</nlm-citation>
</ref>
<ref id="CIT0023">
<label>23</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gebremichael</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Voth</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>An intrinsic bending and structural rearrangement of tubulin dimer: molecular dynamics simulation and coarse-grained analysis</article-title>
<source>Biophys J</source>
<year>2008</year>
<volume>95</volume>
<issue>5</issue>
<fpage>2487</fpage>
<lpage>2499</lpage>
</nlm-citation>
</ref>
<ref id="CIT0024">
<label>24</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Horwitz</surname>
<given-names>SB</given-names>
</name>
</person-group>
<article-title>Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines</article-title>
<source>Mol Cancer Ther</source>
<year>2001</year>
<volume>1</volume>
<issue>1</issue>
<fpage>3</fpage>
<lpage>10</lpage>
</nlm-citation>
</ref>
<ref id="CIT0025">
<label>25</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daly</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Entropy and enthalpy in the activity of tubulin-based antimitotic agents</article-title>
<source>Curr Chem Biol</source>
<year>2009</year>
<volume>3</volume>
<issue>1</issue>
<fpage>367</fpage>
<lpage>379</lpage>
</nlm-citation>
</ref>
<ref id="CIT0026">
<label>26</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kenneth</surname>
<given-names>H. Downing</given-names>
</name>
<name>
<surname>Nogales</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Crystallographic structure of tubulin: implications for dynamics and drug binding</article-title>
<source>Cell Struct Funct</source>
<year>1999</year>
<volume>24</volume>
<issue>5</issue>
<fpage>269</fpage>
<lpage>275</lpage>
</nlm-citation>
</ref>
<ref id="CIT0027">
<label>27</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jordan</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Microtubules as a target for anticancer drugs</article-title>
<source>Nat Rev Cancer</source>
<year>2004</year>
<volume>4</volume>
<issue>4</issue>
<fpage>253</fpage>
<lpage>265</lpage>
</nlm-citation>
</ref>
<ref id="CIT0028">
<label>28</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sept</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Taxol allosterically alters the dynamics of the tubulin dimer and increases the flexibility of microtubules</article-title>
<source>Biophys J</source>
<year>2008</year>
<volume>95</volume>
<issue>7</issue>
<fpage>3252</fpage>
<lpage>3258</lpage>
</nlm-citation>
</ref>
<ref id="CIT0029">
<label>29</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannakakou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gussio</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nogales</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Downing</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Zaharevitz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bollbuck</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>2000</year>
<volume>97</volume>
<issue>6</issue>
<fpage>2904</fpage>
<lpage>2909</lpage>
</nlm-citation>
</ref>
<ref id="CIT0030">
<label>30</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berrieman</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Lind</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Cawkwell</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Do beta-tubulin mutations have a role in resistance to chemotherapy?</article-title>
<source>Lancet Oncol</source>
<year>2004</year>
<volume>5</volume>
<issue>3</issue>
<fpage>158</fpage>
<lpage>164</lpage>
</nlm-citation>
</ref>
<ref id="CIT0031">
<label>31</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dozier</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Hiser</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Tucci</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Benghuzzi</surname>
<given-names>HA</given-names>
</name>
<etal/>
</person-group>
<article-title>Beta class II tubulin predominates in normal and tumor breast tissues</article-title>
<source>Breast Cancer Res</source>
<year>2003</year>
<volume>5</volume>
<issue>5</issue>
<fpage>R157</fpage>
<lpage>169</lpage>
</nlm-citation>
</ref>
<ref id="CIT0032">
<label>32</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferguson</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stanley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Joyce</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harnden</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Resistance to the tubulin-bind-ing agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression</article-title>
<source>Clin Cancer Res</source>
<year>2005</year>
<volume>11</volume>
<issue>9</issue>
<fpage>3439</fpage>
<lpage>3445</lpage>
</nlm-citation>
</ref>
<ref id="CIT0033">
<label>33</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavallaris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tait</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Horwitz</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Norris</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>
<article-title>Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells</article-title>
<source>Cancer Res</source>
<year>2001</year>
<volume>61</volume>
<issue>15</issue>
<fpage>5803</fpage>
<lpage>5809</lpage>
</nlm-citation>
</ref>
<ref id="CIT0034">
<label>34</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mozzetti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ferlini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Concolino</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Filippetti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Raspaglio</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Prislei</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Class III beta-tubulin overexpression is a prominent mechanism of pacli-taxel resistance in ovarian cancer patients</article-title>
<source>Clin Cancer Res</source>
<year>2005</year>
<volume>11</volume>
<issue>1</issue>
<fpage>298</fpage>
<lpage>305</lpage>
</nlm-citation>
</ref>
<ref id="CIT0035">
<label>35</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasannan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Misek</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Hinderer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Michon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Geiger</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Hanash</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma</article-title>
<source>Clin Cancer Res</source>
<year>2000</year>
<volume>6</volume>
<issue>10</issue>
<fpage>3949</fpage>
<lpage>3956</lpage>
</nlm-citation>
</ref>
<ref id="CIT0036">
<label>36</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranganathan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dexter</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Benetatos</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Tew</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Hudes</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Increase of beta (III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance</article-title>
<source>Cancer Res</source>
<year>1996</year>
<volume>56</volume>
<issue>11</issue>
<fpage>2584</fpage>
<lpage>2589</lpage>
</nlm-citation>
</ref>
<ref id="CIT0037">
<label>37</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sullivan</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Cleveland</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1986</year>
<volume>83</volume>
<issue>12</issue>
<fpage>4327</fpage>
<lpage>4331</lpage>
</nlm-citation>
</ref>
<ref id="CIT0038">
<label>38</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bairoch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boeckmann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ferro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gasteiger</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Swisss-Prot: juggling between evolution and stability</article-title>
<source>Brief Bioinform</source>
<year>2004</year>
<volume>5</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>55</lpage>
</nlm-citation>
</ref>
<ref id="CIT0039">
<label>39</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altschul</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Madden</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Miler</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Gapped BLAST and PSI-BLAST: a new generation of protein database search programs</article-title>
<source>Nucleic Acids Res</source>
<year>1997</year>
<volume>25</volume>
<issue>17</issue>
<fpage>3389</fpage>
<lpage>3402</lpage>
</nlm-citation>
</ref>
<ref id="CIT0040">
<label>40</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lowe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Downing</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Nogales</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Refined structure of &#x3B1;&#x3B2; tubulin at 3.5&#x00C5; resolution</article-title>
<source>J Mol Biol</source>
<year>2001</year>
<volume>313</volume>
<issue>5</issue>
<fpage>1045</fpage>
<lpage>1057</lpage>
</nlm-citation>
</ref>
<ref id="CIT0041">
<label>41</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sali</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Blundell</surname>
<given-names>TL</given-names>
</name>
</person-group>
<article-title>Comparative protein modelling by satisfaction of spatial restraints</article-title>
<source>J Mol Biol</source>
<year>1993</year>
<volume>234</volume>
<issue>3</issue>
<fpage>779</fpage>
<lpage>815</lpage>
</nlm-citation>
</ref>
<ref id="CIT0042">
<label>42</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guex</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Peitsch</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling</article-title>
<source>Electrophoresis</source>
<year>1997</year>
<volume>18</volume>
<issue>15</issue>
<fpage>2714</fpage>
<lpage>2723</lpage>
</nlm-citation>
</ref>
<ref id="CIT0043">
<label>43</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laskowski</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>MacArthur</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>PROCHECK-a program to check the stereochemical quality of protein structures</article-title>
<source>J App Cryst</source>
<year>1993</year>
<volume>26</volume>
<fpage>283</fpage>
<lpage>291</lpage>
</nlm-citation>
</ref>
<ref id="CIT0044">
<label>44</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Vasanthi</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Seaweed metabolite database (SWMD): A database of natural compounds from marine algae</article-title>
<source>Bioinformation</source>
<year>2011</year>
<volume>5</volume>
<issue>8</issue>
<fpage>361</fpage>
<lpage>364</lpage>
</nlm-citation>
</ref>
<ref id="CIT0045">
<label>45</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kurosawa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Komiyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The structures of cytotoxic diterpenes containing bromine from the marine red alga Laurencia obtusa (Hudson) Lamouroux</article-title>
<source>Bull Chem Soc Jpn</source>
<year>1990</year>
<volume>63</volume>
<issue>11</issue>
<fpage>3066</fpage>
<lpage>3072</lpage>
</nlm-citation>
</ref>
<ref id="CIT0046">
<label>46</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Duh</surname>
<given-names>CH</given-names>
</name>
</person-group>
<article-title>Cytotoxic oxygenated desmosterols of the red alga Galaxaura marginata</article-title>
<source>J Nat Prod</source>
<year>1996</year>
<volume>59</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>26</lpage>
</nlm-citation>
</ref>
<ref id="CIT0047">
<label>47</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheu</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Duh</surname>
<given-names>CY</given-names>
</name>
</person-group>
<article-title>Study on cytotoxic oxygenated desmosterols isolated from the red alga Galaxaura marginata</article-title>
<source>J Nat Prod</source>
<year>1997</year>
<volume>60</volume>
<issue>9</issue>
<fpage>900</fpage>
<lpage>903</lpage>
</nlm-citation>
</ref>
<ref id="CIT0048">
<label>48</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kladi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xenaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vagias</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Papazafiri</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Roussis</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>New cytotoxic sesquiterpenes from the red algae Laurencia obtuse and Laurencia microcladia</article-title>
<source>Tetrahedron</source>
<year>2006</year>
<volume>62</volume>
<issue>1</issue>
<fpage>182</fpage>
<lpage>189</lpage>
</nlm-citation>
</ref>
<ref id="CIT0049">
<label>49</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ilopoulou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mihopoulos</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vigias</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Papazafiri</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Roussis</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Novel cytotoxic brominated diter-penes from the red alga Laurencia obtuse</article-title>
<source>J Org Chem</source>
<year>2003</year>
<volume>68</volume>
<issue>20</issue>
<fpage>7667</fpage>
<lpage>7674</lpage>
</nlm-citation>
</ref>
<ref id="CIT0050">
<label>50</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selvaa</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Gadewal</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Mohammed</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Identification of leads from marine seaweeds against human &#x3B2;-tubulin</article-title>
<source>Lett Drug Des Discov</source>
<year>2013</year>
<volume>10</volume>
<issue>1</issue>
<fpage>67</fpage>
<lpage>74</lpage>
</nlm-citation>
</ref>
<ref id="CIT0051">
<label>51</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Simultaneous determination of jatrorrhizine, palmatine, berberine, and obacunone in Phellodendri amurensis cortex by RP-HPLC</article-title>
<source>Zhongguo Zhong Yao Za Zhi</source>
<year>2010</year>
<volume>35</volume>
<issue>16</issue>
<fpage>2061</fpage>
<lpage>2064</lpage>
<comment>Chinese</comment>
</nlm-citation>
</ref>
<ref id="CIT0052">
<label>52</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>RZ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>XY</given-names>
</name>
</person-group>
<article-title>Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells</article-title>
<source>Acta Pharmacol Sin</source>
<year>2009</year>
<volume>30</volume>
<issue>12</issue>
<fpage>1659</fpage>
<lpage>1665</lpage>
</nlm-citation>
</ref>
<ref id="CIT0053">
<label>53</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chowdhury</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mittra</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mukhopadhyay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Majumder</surname>
<given-names>HK</given-names>
</name>
</person-group>
<article-title>Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives</article-title>
<source>Med Sci Monit</source>
<year>2002</year>
<volume>8</volume>
<issue>7</issue>
<fpage>BR254</fpage>
<lpage>265</lpage>
</nlm-citation>
</ref>
<ref id="CIT0054">
<label>54</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pezzuto</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation</article-title>
<source>Clin Cancer Res</source>
<year>2003</year>
<volume>9</volume>
<issue>7</issue>
<fpage>2866</fpage>
<lpage>2875</lpage>
</nlm-citation>
</ref>
<ref id="CIT0055">
<label>55</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Efferth</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Zu</surname>
<given-names>YG</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Konkimalla</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Wink</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine</article-title>
<source>Curr Med Chem</source>
<year>2007</year>
<volume>14</volume>
<issue>19</issue>
<fpage>2024</fpage>
<lpage>2032</lpage>
</nlm-citation>
</ref>
<ref id="CIT0056">
<label>56</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dakeng</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Duangmano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jiratchariyakul</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Upratya</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>B&#x00F6;gler</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Patmasiriwat</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Cell inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated &#x3B2;-catenin to the nucleus</article-title>
<source>J Cell Biochem</source>
<year>2012</year>
<volume>113</volume>
<issue>1</issue>
<fpage>49</fpage>
<lpage>60</lpage>
</nlm-citation>
</ref>
<ref id="CIT0057">
<label>57</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllo-toxins: 2003-2007</article-title>
<source>Curr Med Chem</source>
<year>2009</year>
<volume>16</volume>
<issue>3</issue>
<fpage>327</fpage>
<lpage>349</lpage>
</nlm-citation>
</ref>
<ref id="CIT0058">
<label>58</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordaliza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Garc&#x00ED;a</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>del Corral</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>G&#x00F3;mez-Zurita</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives</article-title>
<source>Toxicon</source>
<year>2004</year>
<volume>44</volume>
<issue>4</issue>
<fpage>441</fpage>
<lpage>459</lpage>
</nlm-citation>
</ref>
<ref id="CIT0059">
<label>59</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damayanthi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lown</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Podophyllotoxins: current status and recent developments</article-title>
<source>Curr Med Chem</source>
<year>1998</year>
<volume>5</volume>
<issue>3</issue>
<fpage>205</fpage>
<lpage>252</lpage>
</nlm-citation>
</ref>
<ref id="CIT0060">
<label>60</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>BY</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Kinghorn</surname>
<given-names>AD</given-names>
</name>
<etal/>
</person-group>
<article-title>Silvestrol a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7</article-title>
<source>Anticancer Res</source>
<year>2007</year>
<volume>27</volume>
<issue>4B</issue>
<fpage>2175</fpage>
<lpage>2183</lpage>
</nlm-citation>
</ref>
<ref id="CIT0061">
<label>61</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Zittoun</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Homoharringto-nine: an effective new natural product in cancer chemotherapy</article-title>
<source>Bull Cancer</source>
<year>1995</year>
<volume>82</volume>
<issue>12</issue>
<fpage>987</fpage>
<lpage>995</lpage>
</nlm-citation>
</ref>
<ref id="CIT0062">
<label>62</label>
<nlm-citation citation-type="journal">
<article-title>Chinese People&#x0027;s Liberation Army 187th Hospital: Harringtonine in acute leukemia: Clinical analysis of 31 cases</article-title>
<source>Chin Med J</source>
<year>1977</year>
<volume>3</volume>
<fpage>319</fpage>
</nlm-citation>
</ref>
<ref id="CIT0063">
<label>63</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Senderowicz</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials</article-title>
<source>Invest New Drugs</source>
<year>1999</year>
<volume>17</volume>
<issue>3</issue>
<fpage>313</fpage>
<lpage>320</lpage>
</nlm-citation>
</ref>
<ref id="CIT0064">
<label>64</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>GQ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Extraction optimisation of daphnoretin from root bark of Wikstroemia indica (L.) C.A. and its anti-tumour activity tests</article-title>
<source>Food Chem</source>
<year>2011</year>
<volume>124</volume>
<issue>4</issue>
<fpage>1500</fpage>
<lpage>1506</lpage>
</nlm-citation>
</ref>
<ref id="CIT0065">
<label>65</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stiborova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bieler</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Wiessler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frei</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts</article-title>
<source>Bio-chem Pharmacol</source>
<year>2001</year>
<volume>62</volume>
<issue>12</issue>
<fpage>1675</fpage>
<lpage>1684</lpage>
</nlm-citation>
</ref>
<ref id="CIT0066">
<label>66</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jensen</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Demant</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Friche</surname>
<given-names>E</given-names>
</name>
<name>
<surname>S&#x00F8;rensen</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Sehested</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II</article-title>
<source>Cancer Res</source>
<year>1991</year>
<volume>51</volume>
<issue>19</issue>
<fpage>5093</fpage>
<lpage>5099</lpage>
</nlm-citation>
</ref>
<ref id="CIT0067">
<label>67</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vetrivel</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Dharmalingam</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Isolation and characterization of stable mutants of Streptomyces peucetius defective in daunorubicin biosynthesis</article-title>
<source>J Genet</source>
<year>2001</year>
<volume>80</volume>
<issue>1</issue>
<fpage>31</fpage>
<lpage>38</lpage>
</nlm-citation>
</ref>
<ref id="CIT0068">
<label>68</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zabriskie</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Streptomyces lividans blasticidin S deaminase and its application in engineering a blasticidin S-producing strain for ease of genetic manipulation</article-title>
<source>Appl Environ Microbiol</source>
<year>2013</year>
<volume>79</volume>
<issue>7</issue>
<fpage>2349</fpage>
<lpage>2357</lpage>
</nlm-citation>
</ref>
<ref id="CIT0069">
<label>69</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Jakobi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Welzel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hertweck</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Biosynthesis of the antitumor agent chartreusin involves the oxidative rearrangement of an anthracyclic polyke-tide</article-title>
<source>Chem Biol</source>
<year>2005</year>
<volume>12</volume>
<issue>5</issue>
<fpage>579</fpage>
<lpage>588</lpage>
</nlm-citation>
</ref>
<ref id="CIT0070">
<label>70</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miyamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ishizuka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Naganawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Neothramycins A and B, new antitumor antibiotics</article-title>
<source>J Antibiot (Tokyo)</source>
<year>1976</year>
<volume>29</volume>
<issue>1</issue>
<fpage>93</fpage>
<lpage>96</lpage>
</nlm-citation>
</ref>
<ref id="CIT0071">
<label>71</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Untch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sevin</surname>
<given-names>BU</given-names>
</name>
<name>
<surname>Perras</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Angioli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Baibl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>HN</given-names>
</name>
<etal/>
</person-group>
<article-title>Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro</article-title>
<source>Gynecol Oncol</source>
<year>1992</year>
<volume>47</volume>
<issue>2</issue>
<fpage>172</fpage>
<lpage>178</lpage>
</nlm-citation>
</ref>
<ref id="CIT0072">
<label>72</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hortobagyi</surname>
<given-names>GN</given-names>
</name>
<name>
<surname>Theriault</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Fraschini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tashima</surname>
<given-names>CK</given-names>
</name>
<etal/>
</person-group>
<article-title>Pirarubicin in com-bination chemotherapy for metastatic breast cancer</article-title>
<source>Am J Clin Oncol</source>
<year>1990</year>
<volume>13</volume>
<supplement>Suppl 1</supplement>
<fpage>S54</fpage>
<lpage>56</lpage>
</nlm-citation>
</ref>
<ref id="CIT0073">
<label>73</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Goddard</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Couch</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>EC</given-names>
</name>
<etal/>
</person-group>
<article-title>UCSF Chimera-a visualization system for exploratory research and analysis</article-title>
<source>J Comput Chem</source>
<year>2004</year>
<volume>25</volume>
<issue>13</issue>
<fpage>1605</fpage>
<lpage>1612</lpage>
</nlm-citation>
</ref>
<ref id="CIT0074">
<label>74</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CC</given-names>
</name>
</person-group>
<article-title>GEMDOCK: A generic evolutionary method for molecular docking</article-title>
<source>Proteins</source>
<year>2004</year>
<volume>55</volume>
<issue>2</issue>
<fpage>288</fpage>
<lpage>304</lpage>
</nlm-citation>
</ref>
<ref id="CIT0075">
<label>75</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbari</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Moghim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reza Mofid</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Comparison of epothilone and taxol binding in yeast tubulin using molecular modeling</article-title>
<source>Avicenna J Med Biotechnol</source>
<year>2011</year>
<volume>3</volume>
<issue>4</issue>
<fpage>167</fpage>
<lpage>175</lpage>
</nlm-citation>
</ref>
<ref id="CIT0076">
<label>76</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stitziel</surname>
<given-names>NO</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Pervouchine</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Goddeau</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kasif</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Structural location of disease-associated single-nucleotide polymorphisms</article-title>
<source>J Mol Biol</source>
<year>2003</year>
<volume>327</volume>
<issue>5</issue>
<fpage>1021</fpage>
<lpage>1030</lpage>
</nlm-citation>
</ref>
<ref id="CIT0077">
<label>77</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stitziel</surname>
<given-names>NO</given-names>
</name>
<name>
<surname>Binkowski</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Kasif</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>topo SNP: a topographic database of non-synonymous single nucleotide polymorphisms with and without known disease association</article-title>
<source>Nucleic Acids Res</source>
<year>2004</year>
<volume>32</volume>
<issue>Database issue</issue>
<fpage>D520</fpage>
<lpage>522</lpage>
</nlm-citation>
</ref>
<ref id="CIT0078">
<label>78</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Kejariwal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Karlak</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Daverman</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>PANTHER: A library of protein families and subfamilies indexed by function</article-title>
<source>Genome Res</source>
<year>2003</year>
<volume>13</volume>
<issue>9</issue>
<fpage>2129</fpage>
<lpage>2141</lpage>
</nlm-citation>
</ref>
<ref id="CIT0079">
<label>79</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capriotti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fariselli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Casadio</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>I-Mutant 2.0: predicting stability changes upon mutation from the protein sequence or structure</article-title>
<source>Nucleic Acids Res</source>
<year>2005</year>
<volume>33</volume>
<issue>Web Server issue</issue>
<fpage>W306</fpage>
<lpage>310</lpage>
</nlm-citation>
</ref>
<ref id="CIT0080">
<label>80</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selvaakumar</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sudheer</surname>
<given-names>MMM</given-names>
</name>
</person-group>
<article-title>An in silico based understanding of drug resistance and residual deletion in tubulin protein from sequential and structural perspective</article-title>
<source>Res J Biotech</source>
<year>2003</year>
<volume>8</volume>
<issue>8</issue>
<fpage>20</fpage>
<lpage>29</lpage>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
